AstraZeneca Presents 5-Year Overall Survival Data for Imfinzi in Stage III NSCLC

AstraZeneca today announced 5-year overall survival (OS) data from the Phase 3 PACIFIC trial showing that Imfinzi (durvalumab) provides durable long-term benefit in patients with unresectable Stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy. At 5 years, the OS rate was 42.9% for Imfinzi versus 33.4% for placebo. The median OS was 47.5 months for Imfinzi versus 29.1 months for placebo. These results demonstrate the exceptional long-term benefit of Imfinzi in Stage III NSCLC and confirm its role as the standard of care in this setting.